OBJECTIVE: The concentration, and the degree of fucosylation and sialylation of human serum alpha 1-acid glycoprotein (AGP) were investigated for changes during 24-week low-dose methotrexate (MTX) or azathioprine treatment (AZA) in rheumatoid arthritis (RA) patients. METHODS: Serum samples from a longitudinal study were analyzed by crossed affinoimmunoelectrophoresis with the fucose specific Aleuria aurantia lectin. RESULTS: In general, the degree of fucosylation of AGP in RA sera was higher than in control sera, but decreased markedly under the influence of successful therapy with MTX. Concomitantly, the degree of sialylation of AGP increased and the concentration decreased. For alpha 1-protease inhibitor and haptoglobin similar results were obtained. In AZA responders less pronounced changes than in MTX responders were observed. In MTX nonresponders no significant trends were found. As in control sera, large interindividual differences in the AGP values were found. CONCLUSION: The heavy fucosylation of AGP in RA sera reflects disease activity rather than an intrinsic characteristic of people genetically predisposed to RA, since it was found to decrease upon disease improvement. The differences in effects on AGP of MTX and AZA suggest either a gradual difference in a similar mechanism of action, or a different mechanism of action of the drugs. Fucosylated and sialylated AGP could be important in the etiopathogenesis of RA, because these molecules potentially can bind to adhesion receptors (selectins), which could prevent the extravasation of leukocytes into inflamed joints.
RCT Entities:
OBJECTIVE: The concentration, and the degree of fucosylation and sialylation of human serum alpha 1-acid glycoprotein (AGP) were investigated for changes during 24-week low-dose methotrexate (MTX) or azathioprine treatment (AZA) in rheumatoid arthritis (RA) patients. METHODS: Serum samples from a longitudinal study were analyzed by crossed affinoimmunoelectrophoresis with the fucose specific Aleuria aurantia lectin. RESULTS: In general, the degree of fucosylation of AGP in RA sera was higher than in control sera, but decreased markedly under the influence of successful therapy with MTX. Concomitantly, the degree of sialylation of AGP increased and the concentration decreased. For alpha 1-protease inhibitor and haptoglobin similar results were obtained. In AZA responders less pronounced changes than in MTX responders were observed. In MTX nonresponders no significant trends were found. As in control sera, large interindividual differences in the AGP values were found. CONCLUSION: The heavy fucosylation of AGP in RA sera reflects disease activity rather than an intrinsic characteristic of people genetically predisposed to RA, since it was found to decrease upon disease improvement. The differences in effects on AGP of MTX and AZA suggest either a gradual difference in a similar mechanism of action, or a different mechanism of action of the drugs. Fucosylated and sialylated AGP could be important in the etiopathogenesis of RA, because these molecules potentially can bind to adhesion receptors (selectins), which could prevent the extravasation of leukocytes into inflamed joints.
Authors: Lampros Fotis; Nurmohammad Shaikh; Kevin W Baszis; Charles M Samson; Raffi Lev-Tzion; Anthony R French; Phillip I Tarr Journal: J Rheumatol Date: 2017-09-15 Impact factor: 4.666
Authors: D C Poland; J P Drenth; E Rabinovitz; A Livneh; J Bijzet; B van het Hof; W van Dijk Journal: Ann Rheum Dis Date: 2001-08 Impact factor: 19.103
Authors: E C Havenaar; R J Dolhain; G A Turner; M T Goodarzi; E C van Ommen; F C Breedveld; W van Dijk Journal: Glycoconj J Date: 1997-06 Impact factor: 2.916
Authors: Anna Olewicz-Gawlik; Izabela Korczowska-Łacka; Jan K Łacki; Kamilla Klama; Paweł Hrycaj Journal: Clin Rheumatol Date: 2007-02-20 Impact factor: 2.980
Authors: E C Havenaar; J S Axford; E C Brinkman-van der Linden; A Alavi; E C Van Ommen; B van het Hof; T Spector; A Mackiewicz; W Van Dijk Journal: Glycoconj J Date: 1998-07 Impact factor: 2.916
Authors: Rob J Rentenaar; Vera M R Heydendael; Frank N J van Diepen; Menno A de Rie; Ineke J M ten Berge Journal: J Clin Immunol Date: 2004-07 Impact factor: 8.317